Given the features of tumor immune infiltration have been acknowledged as pivotal factors impacting the response to immunotherapy [31], we hypothesized that CCL21 might potentiate the efficacy of ICIs in HCC. This evidence concerns the gene CCL21 and hepatocellular carcinoma.